



Alexander Dinur

Counsel

New Jersey

T: +1 973.422.6732 | F: +1 973.597.2400

adinur@lowenstein.com

Alex's practice focuses on a broad range of capital markets, M&A, private equity, corporate governance, securities compliance, and corporate finance matters. He is experienced in drafting documentation and developing strategy for all stages of public offerings and private placements of debt and equity securities, including IPOs, follow-on offerings, and Rule 144A offerings representing underwriters, agents, and issuers.

He regularly advises clients on corporate governance and securities compliance issues, including Securities and Exchange Act reporting. Alex also drafts governance documents such as committee charters, and he prepares ancillary documents for credit facilities, private placements, and other forms of debt financing.

Alex's recent focus has been on technology and life sciences companies in the small- to mid-cap markets. In that capacity, he serves as a trusted counselor to senior management by giving thoughtful advice and attentive service.

EXPERIENCE

- > Represented Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat and prevent disease and alleviate pain, in a \$70 million At-the-Market-Offering.
- > Represented Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine in oncology through the use of biomarkers and molecular testing, in connection with a definitive merger agreement with StemoniX, Inc., developer and manufacturer of high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development, anticipated to result in a total post-money equity value of the combined company of approximately \$70 million.
- > Represented H.C. Wainwright & Co., LLC, as lead agent, in a \$50 million at the market offering of common shares of Mogo Inc. (TSX: MOGO; NASDAQ: MOGO), a financial technology company based in Vancouver, Canada.
- > Represented Sonnet BioTherapeutics, Inc., a privately-held clinical stage biopharmaceutical company developing innovative targeted biologic drugs, in connection with its merger with Chanticleer Holdings, Inc. to form a company operating under the name Sonnet BioTherapeutics Holdings, Inc., with its shares trading on the Nasdaq Capital Market under the ticker symbol "SONN" and in connection with a private placement of \$19 million and the acquisition of the global development rights for Atexakin Alfa from Relief Therapeutics SA.
- > Represented BTIG, LLC, as sole book-running manager, in connection with a \$42 million underwritten public offering of common stock of OncoSec Medical Incorporated (NASDAQ:ONCS), a late-stage biotechnology company.
- > Represented Timber Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, in connection with a \$25 million private placement of common stock and warrants.
- > Represented Celldex Therapeutics, Inc. (NASDAQ: CLDX), a biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics, in connection with a \$130.4 million public offering of common stock.
- > Represented Corbus Pharmaceuticals Holdings, Inc. in connection with a \$50 million at-the-market-offering.
- > Represented H.C. Wainwright & Co., as sole book-running manager, in connection with a \$28.75 million underwritten public offering of common stock of Aytu BioScience, Inc. (NASDAQ: AYTU), a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.

HONORS & AWARDS

- > **The Best Lawyers in America (2021-2022)**
Recognized as "One to Watch" in the Corporate Governance and Compliance Law / Mergers and Acquisitions sections

NEWS & INSIGHTS

Publications

- > July 16, 2020
"U.S. Department of Labor Proposes New (Simpler) Fiduciary Rule Exemption," *Employee Benefits & Executive Compensation and Investment Management Client Alert*
Andrew E. Graw, Megan Monson,
- > July 2, 2018
"How Regulation A Updates Could Benefit Smaller Reporting Companies," *Corporate Counsel*
John D. "Jack" Hogoboom, Alan Wovsaniker, Alexander Dinur
- > June 5, 2018
"Regulation A Availability for Securities Offerings by Smaller Reporting Companies," *Capital Markets & Securities Client Alert*
Alexander Dinur, Alan Wovsaniker, John D. "Jack" Hogoboom
- > June 12, 2017
"What Can I Find Out About a Company From Its Website?," *Bloomberg Law*
John D. "Jack" Hogoboom, Alexander Dinur

In the Media

- > June 22, 2020
Lowenstein's representation of issuer **Celldex Therapeutics, Inc.** (Celldex) (Nasdaq: CLDX) in connection with the company's approximately \$150 million public offering of common stock is highlighted in the **Global Legal Chronicle**. The Lowenstein team included **Anthony O. Pergola, Alan Wovsaniker, Kate Basmagian, Alexander Dinur**, Madeline Roe, **Sarah Gore**, and **Robert J. Paradiso**. [View Lowenstein's news announcement about this transaction.](#)
- > January 29, 2020
Lowenstein's representation of **Timber Pharmaceuticals** in its definitive merger agreement with BioPharmX Corporation was noted in **citybizlist, ROI-NJ, BioWorld**, and **Cision PR Newswire**. The Lowenstein deal team included **Steven M. Skolnick, Alan Wovsaniker, Alexander Dinur**, and **Tracy F. Buffer**. [View Lowenstein's news announcement about this transaction.](#)

EDUCATION

- > Northwestern University School of Law (J.D. 2013), cum laude; Senior Editor, *Journal of International Law and Business*
- > Rice University (B.A. 2009), Economics with honors; Trustee Distinguished Scholar; Century Scholar; Economics Honor Society

ADMISSIONS

- > New Jersey
- > Texas